Hikma Pharmaceuticals Plc Circ re. Roxane Acquisition (8101O)
February 11 2016 - 7:19AM
UK Regulatory
TIDMHIK
RNS Number : 8101O
Hikma Pharmaceuticals Plc
11 February 2016
Publication of supplementary circular
London, 11 February 2016 - Hikma Pharmaceuticals PLC ("Hikma" or
the "Company") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the
fast growing pharmaceuticals company, has today published a
supplementary combined prospectus and circular (the "Supplementary
Prospectus") which is a supplement to the combined prospectus and
circular published by the Company on 22 January 2016 in relation to
the Acquisition and Consideration Shares (the "Prospectus").
The publication of the Supplementary Prospectus is a regulatory
requirement under the Listing Rules and Prospectus Rules following
the announcement made by the Company on 10 February 2016. The
Supplementary Prospectus should be read in conjunction with the
Prospectus.
As required by Listing Rules 9.6.1R and 9.6.3R and Prospectus
Rule 3.2.1R and 3.4.3R, a copy of the Supplementary Prospectus has
been approved by the Financial Conduct Authority and published and
submitted to the National Storage Mechanism and will shortly be
available for inspection at www.morningstar.co.uk/uk/NSM .
Posting of the Supplementary Prospectus is expected to be
completed on 11 February 2016. You will find enclosed with the
Supplementary Prospectus an additional Form of Proxy for use at the
General Meeting to assist Shareholders in voting on the
Resolutions. Shareholders may return either the original Form of
Proxy or the Form of Proxy enclosed with the Supplementary
Prospectus. If two or more valid but differing Forms of Proxy are
delivered in respect of the same share for use at the General
Meeting, the one which is last delivered (regardless of its date,
its date of sending or the date of its execution) shall be treated
as replacing and revoking the others as regards that share.
As set out in the announcement made by the Company on 10
February 2016, the Board continues to unanimously recommend that
the Shareholders vote in favour of the Resolutions at the General
Meeting, to be held at 9.00a.m. on 19 February 2016 at The
Westbury, Bond Street, Mayfair, London W1S 2YF.
Capitalised terms used in this announcement have the meanings
given to them in the Prospectus. The Prospectus and Supplementary
Prospectus are available on the Company's website
(www.hikma.com/en/investors/shareholder-services/circular-and-egm.aspx)
and may be inspected at the office of the Company's counsel at
Slaughter and May, One Bunhill Row, London, EC1Y 8YY.
Enquiries
Hikma Pharmaceuticals PLC
Peter Speirs, Company Secretary
+44 (0)20 7399 2772
Susan Ringdal, Vice President, Corporate Strategy
& Investor Relations +44 (0)20 7399 2760
FTI Consulting
Matthew Cole & Ben Atwell +44 (0)20 3727 1000
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based primarily in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe. In 2014, Hikma achieved
revenues of $1,489 million and profit attributable to shareholders
of $278 million.
Disclaimer
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT
CONSTITUTE A PROSPECTUS OR EQUIVALENT. INVESTORS SHOULD NOT
SUBSCRIBE FOR OR PURCHASE ANY SECURITIES REFERRED TO IN THIS
ANNOUNCEMENT. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN INVITATION
OR OFFER TO SELL OR EXCHANGE OR THE SOLICITATION OF AN INVITATION
OR OFFER TO BUY OR EXCHANGE ANY SECURITIES IN THE UNITED STATES OR
ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DO SO PRIOR TO
REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF SUCH
JURISDICTION. NONE OF THE SECURITIES REFERRED TO IN THIS
ANNOUNCEMENT SHALL BE SOLD, ISSUED, EXCHANGED OR TRANSFERRED IN ANY
JURISDICTION IN CONTRAVENTION OF APPLICABLE LAW. THE SECURITIES
HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE SECURITIES
ACT, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR
OTHER JURISDICTION AND ARE BEING OFFERED AND SOLD IN RELIANCE UPON
AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE
REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND ANY APPLICABLE
STATE OR LOCAL SECURITIES LAWS. THERE WILL BE NO PUBLIC OFFERING OF
SECURITIES IN THE UNITED STATES.
CITIGROUP GLOBAL MARKETS LIMITED ("CITI"), WHICH IS AUTHORISED
BY THE PRUDENTIAL REGULATION AUTHORITY AND REGULATED BY THE
FINANCIAL CONDUCT AUTHORITY AND THE PRUDENTIAL REGULATION
AUTHORITY, IS ACTING EXCLUSIVELY FOR HIKMA AND NO ONE ELSE IN
CONNECTION WITH THE ACQUISITION AND WILL NOT BE RESPONSIBLE TO
ANYONE OTHER THAN HIKMA FOR PROVIDING THE PROTECTIONS AFFORDED TO
CLIENTS OF CITI OR FOR PROVIDING ADVICE IN RELATION TO THE
ACQUISITION OR ANY OTHER MATTERS REFERRED TO IN THIS ANNOUNCEMENT.
NEITHER CITI NOR ANY OF ITS DIRECTORS, OFFICERS, REPRESENTATIVES,
EMPLOYEES, ADVISERS, AGENTS OR AFFILIATES OWES OR ACCEPTS ANY DUTY,
LIABILITY OR RESPONSIBILITY WHATSOEVER (WHETHER IN CONTRACT, IN
TORT, UNDER STATUTE OR OTHERWISE) TO ANY PERSON WHO IS NOT A CLIENT
OF CITI IN CONNECTION WITH THIS ANNOUNCEMENT, ANY STATEMENT
CONTAINED HEREIN, THE ACQUISITION OR OTHERWISE.
-- ENDS --
This information is provided by RNS
The company news service from the London Stock Exchange
END
CIRMMGMZZMRGVZM
(END) Dow Jones Newswires
February 11, 2016 07:19 ET (12:19 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024